Isolation of Leishmania amastigote protein fractions which induced lymphocyte stimulation and remission of psoriasis

A first generation polyvalent vaccine (AS100¹) was manufactured with protein from several cultured leishmania species, which proved to be effective in the treatment of psoriasis. To determine the effective factor, a single blind trial with four monovalent second generation vaccines (AS100²) was done in 26 subjects, which also resulted in remission of psoriasis. AS100² vaccines were further purified, resulting in seven chromatography fractions (AS200) per species. In vitro testing of the fractions on blood lymphocytes resulted in subjects being categorized as low or high responders before treatment. Both responder groups had no statistical difference in clinical outcome after AS100¹ treatment. Subsequently, a single-blind trial in 55 subjects treated with AS200 fractions from Leishmania brasiliensis also induced remission of Psoriasis. Two HIV ± subjects with plaque psoriasis experienced remission after treatment with AS100¹. There are factors in leishmania species which induce remission of psoriasis by stimulating lymphocytes.